Identification of accessible human cancer biomarkers using ex vivo chemical proteomic strategies

Expert Review of Proteomics

Volumn 4, Issue 6, 2007, Pages 727-739

  Kischel, Philippe ^a   Waltregny, David ^b   Castronovo, Vincent ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Biomarker discovery; Biotinylation; Breast cancer; Tandem mass spectrometry; Tumor targeting

Indexed keywords

CELL PROTEIN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; TUMOR MARKER;

BIOTINYLATION; CANCER RESEARCH; CYTOKINE RELEASE; HUMAN; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN PROCESSING; PROTEIN TRANSPORT; PROTEOMICS; REVIEW; TISSUE MICROARRAY;

ANIMALS; ANTIGENS, NEOPLASM; BODY FLUIDS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; MODELS, BIOLOGICAL; NEOPLASMS; PERFUSION; PROTEOME; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 37149046901     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.4.6.727     Document Type: Review

References (80)

1. Silacci M, Brack S, Schirru G et al. Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics 5(9), 2340-2350 (2005).
2. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23(9), 1147-1157 (2005). •• Important discussion on the use of monoclonal antibodies for targeted anticancer therapies.
3. Collins J, Horn N, Wadenback J, Szardenings M. Cosmix-plexing: a novel recombinatorial approach for evolutionary selection from combinatorial libraries. J. Biotechnol. 74(4), 317-338 (2001).
4. Nimjee SM, Rusconi CP, Sullenger BA. Aptamers: an emerging class of therapeutics. Annu. Rev. Med. 56, 555-583 (2005).
5. Melkko S, Scheuermann J, Dumelin CE, Neri D. Encoded self-assembling chemical libraries. Nat. Biotechnol. 22(5), 568-574 (2004).
6. Chatterjee SK, Zetter BR. Cancer biomarkers: knowing the present and predicting the future. Future Oncol. 1(1), 37-50 (2005). • Useful review describing the history of biomarkers, current biomarkers and their use, as well as some important aspects for clinical applications.
7. Haber DA, Settleman J. Cancer: drivers and passengers. Nature 446(7132), 145-146 (2007).
8. Neve RM, Chin K, Fridlyand J et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10(6), 515-527 (2006).
9. Hondermarck H. Breast cancer: when proteomics challenges biological complexity. Mol. Cell. Proteomics 2(5), 281-291 (2003).
10. Ornstein DK, Gillespie JW, Paweletz CP et al. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 21(11), 2235-2242 (2000).
11. Celis A, Rasmussen HH, Celis P et al. Short-term culturing of low-grade superficial bladder transitional cell carcinomas leads to changes in the expression levels of several proteins involved in key cellular activities. Electrophoresis 20(2), 355-361 (1999).
12. Gupta PB, Kuperwasser C. Disease models of breast cancer. Drug Discov. Today 1(1), 9-16 (2004).
13. Jessani N, Humphrey M, McDonald WH et al. Carcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo. Proc. Natl Acad. Sci. USA 101(38), 13756-13761 (2004).
14. Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell 7(6), 513-520 (2005).
15. Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat. Rev. Cancer 7(2), 139-147 (2007).
16. Santoni V, Molloy M, Rabilloud T. Membrane proteins and proteomics: un amour impossible? Electrophoresis 21(6), 1054-1070 (2000).
17. Jain M, Venkatraman G, Batra SK. Cell-penetrating peptides and antibodies: a new direction for optimizing radioimmunotherapy. Eur. J. Nucl. Med. Mol. Imaging 34(7), 973-977 (2007).
18. WAF-1/Cip-1. Eur. J. Nucl. Med. Mol. Imaging 34(3), 368-377 (2007).
19. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 24(8), 971-983 (2006). •• Outstanding review focusing on the processes included in the biomarker pipeline, such as biomarker discovery and validation steps.
20. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 1(11), 845-867 (2002).
21. Jacobs JM, Adkins JN, Qian WJ et al. Utilizing human blood plasma for proteomic biomarker discovery. J. Proteome Res. 4(4), 1073-1085 (2005).
22. Granger J, Siddiqui J, Copeland S, Remick D. Albumin depletion of human plasma also removes low abundance proteins including the cytokines. Proteomics 5(18), 4713-4718 (2005).
23. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 422(6928), 198-207 (2003). •• Excellent review covering the basic principles of mass spectrometry and describing available devices for mass spectrometry-based biomarker discovery.
24. Rosty C, Christa L, Kuzdzal S et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res. 62(6), 1868-1875 (2002).
25. Celis JE, Gromov P, Cabezon T et al. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol. Cell. Proteomics 3(4), 327-344 (2004).
26. Ruhlen RL, Sauter ER. Proteomics of nipple aspirate fluid, breast cyst fluid, milk, and colostrum. Proteomics 1(8), 845-852 (2007).
27. Emmert-Buck MR, Bonner RF, Smith PD et al. Laser capture microdissection. Science 274(5289), 998-1001 (1996).
28. Baker H, Patel V, Molinolo AA et al. Proteome-wide analysis of head and neck squamous cell carcinomas using laser-capture microdissection and tandem mass spectrometry. Oral Oncol. 41(2), 183-199 (2005).
29. Li C, Hong Y, Tan YX et al. Accurate qualitative and quantitative proteomic analysis of clinical hepatocellular carcinoma using laser capture microdissection coupled with isotope-coded affinity tag and two-dimensional liquid chromatography mass spectrometry. Mol. Cell. Proteomics 3(4), 399-409 (2004).
30. Nettikadan S, Radke K, Johnson J et al. Detection and quantification of protein biomarkers from fewer than 10 cells. Mol. Cell. Proteomics 5(5), 895-901 (2006).
31. Tammen H, Kreipe H, Hess R et al. Expression profiling of breast cancer cells by differential peptide display. Breast Cancer Res. Treat. 79(1), 83-93 (2003).
32. Pucci-Minafra I, Cancemi P, Marabeti MR et al. Proteomic profiling of 13 paired ductal infiltrating breast carcinomas and non-tumoral adjacent counterparts. Proteomics 1(1), 118-129 (2007).
33. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17(10), 994-999 (1999).
34. Saghatelian A, Cravatt BF. Assignment of protein function in the postgenomic era. Nat. Chem. Biol. 1(3), 130-142 (2005).
35. Roesli C, Neri D, Rybak J-N. In vivo protein biotinylation and sample preparation for the proteomic identification of organ- and disease-specific antigens accessible from the vasculature. Nat. Protocols 1(1), 192-199 (2006).
36. Rybak JN, Ettorre A, Kaissling B, Giavazzi R, Neri D, Elia G. In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat. Methods 2(4), 291-298 (2005). •• Description of the in vivo perfusion of tumor bearing mice with reactive esters of biotin.
37. Castronovo V, Waltregny D, Kischel P et al. A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer. Mol. Cell. Proteomics 5(11), 2083-2091 (2006).
38. Lambert JM. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr. Opin. Pharmacol. 5(5), 543-549 (2005).
39. Zardi L, Neri D. Affinity reagents against tumour-associated extracellular molecules and newforming vessels. Adv. Drug Deliv. Rev. 31(1-2), 43-52 (1998).
40. Kaspar M, Zardi L, Neri D. Fibronectin as target for tumor therapy. Int. J. Cancer 118(6), 1331-1339 (2006).
41. Silacci M, Brack SS, Spath N et al. Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng. Des. Sel. 19(10), 471-478 (2006).
42. Castronovo V, Kischel P, Guillonneau F et al. Identification of specific reachable molecular targets in human breast cancer using a versatile ex vivo proteomic method. Proteomics 7(8), 1188-1196 (2007).
43. Holmberg A, Blomstergren A, Nord O, Lukacs M, Lundeberg J, Uhlen M. The biotin-streptavidin interaction can be reversibly broken using water at elevated temperatures. Electrophoresis 26(3), 501-510 (2005).
44. Wulfkuhle JD, Sgroi DC, Krutzsch H et al. Proteomics of human breast ductal carcinoma in situ. Cancer Res. 62(22), 6740-6749 (2002).
45. Bertucci F, Birnbaum D, Goncalves A. Proteomics of breast cancer: principles and potential clinical applications. Mol. Cell. Proteomics 5(10), 1772-1786 (2006).
46. Liu H, Lin D, Yates JR III. Multidimensional separations for protein/peptide analysis in the post-genomic era. Biotechniques 32(4), 898-900, 902 passim (2002).
47. Washburn MP, Wolters D, Yates JR III. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol. 19(3), 242-247 (2001).
48. Olsen JV, de Godoy LM, Li G et al. Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap. Mol. Cell. Proteomics 4(12), 2010-2021 (2005).
49. Schmidt A, Aebersold R. High-accuracy proteome maps of human body fluids. Genome Biol. 7(11), 242 (2006).
50. de Souza GA, Godoy LM, Mann M. Identification of 491 proteins in the tear fluid proteome reveals a large number of proteases and protease inhibitors. Genome Biol. 7(8), R72 (2006).
51. Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M. The human urinary proteome contains more than 1500 proteins including a large proportion of membranes proteins. Genome Biol. 7(9), R80 (2006).
52. Pilch B, Mann M. Large-scale and high-confidence proteomic analysis of human seminal plasma. Genome Biol. 7(5), R40 (2006).
53. Taylor CF, Paton NW, Lilley KS et al. The minimum information about a proteomics experiment (MIAPE). Nat. Biotechnol. 25(8), 887-893 (2007).
54. van der Merwe DE, Oikonomopoulou K, Marshall J, Diamandis EP. Mass spectrometry: uncovering the cancer proteome for diagnostics. Adv. Cancer Res. 96, 23-50 (2007).
55. Rollin D, Whistler T, Vernon SD. Laboratory methods to improve SELDI peak detection and quantitation. Proteome Sci. 5, 9 (2007).
56. Wilkins MR, Appel RD, Van Eyk JE et al. Guidelines for the next 10 years of proteomics. Proteomics 6(1), 4-8 (2006).
57. Carr S, Aebersold R, Baldwin M, Burlingame A, Clauser K, Nesvizhskii A. The need for guidelines in publication of peptide and protein identification data: Working Group on Publication Guidelines for Peptide and Protein Identification Data. Mol. Cell. Proteomics 3(6), 531-533 (2004).
58. Durr E, Yu J, Krasinska KM et al. Direct proteomic mapping of the lung microvascular endothelial cell surface in vivo and in cell culture. Nat. Biotechnol. 22(8), 985-992 (2004).
59. Elias JE, Haas W, Faherty BK, Gygi SP. Comparative evaluation of mass spectrometry platforms used in large-scale proteomics investigations. Nat. Methods 2(9), 667-675 (2005).
60. Annesley TM. Ion suppression in mass spectrometry. Clin. Chem. 49(7), 1041-1044 (2003).
61. Mann M. Functional and quantitative proteomics using SILAC. Nat. Rev. Mol. Cell Biol. 7(12), 952-958 (2006).
62. 18O-labeling strategies for quantitative proteomics. Mass Spectrom. Rev. 26(1), 121-136 (2007).
63. Ross PL, Huang YN, Marchese JN et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using aminereactive isobaric tagging reagents. Mol. Cell. Proteomics 3(12), 1154-1169 (2004).
64. Schmidt A, Kellermann J, Lottspeich F. A novel strategy for quantitative proteomics using isotope-coded protein labels. Proteomics 5(1), 4-15 (2005).
65. Gerber SA, Rush J, Stemman O, Kirschner MW, Gygi SP. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc. Natl Acad. Sci. USA 100(12), 6940-6945 (2003).
66. Bantscheff M, Schirle M, Sweetman G, Rick J, Kuster B. Quantitative mass spectrometry in proteomics: a critical review. Anal. Bioanal. Chem. 389(4), 1017-1031 (2007).
67. Wan WH, Fortuna MB, Furmanski P. A rapid and efficient method for testing immunohistochemical reactivity of monoclonal antibodies against multiple tissue samples simultaneously. J. Immunol. Methods 103(1), 121-129 (1987).
68. Kononen J, Bubendorf L, Kallionimeni A et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 4(7), 844-847 (1998).
69. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics 5(4), 573-588 (2006).
70. Nam JM, Thaxton CS, Mirkin CA. Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science 301(5641), 1884-1886 (2003).
71. Service RF. American Chemical Society meeting. Tiny transistors scout for cancer. Science 300(5617), 242-243 (2003).
72. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J. Clin. Oncol. 25(23), 3525-3533 (2007).
73. Boyd CD, Pierce RA, Schwarzbauer JE, Doege K, Sandell LJ. Alternate exon usage is a commonly used mechanism for increasing coding diversity within genes coding for extracellular matrix proteins. Matrix 13(6), 457-469 (1993).
74. Zardi L, Carnemolla B, Siri A et al. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J. 6(8), 2337-2342 (1987).
75. Carnemolla B, Neri D, Castellani P et al. Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int. J. Cancer 68(3), 397-405 (1996).
76. Neri D, Carnemolla B, Nissim A et al. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat. Biotechnol. 15(12), 1271-1275 (1997).
77. Borsi L, Balza E, Bestagno M et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int. J. Cancer 102(1), 75-85 (2002).
78. Santimaria M, Moscatelli G, Viale GL et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin. Cancer Res. 9(2), 571-579 (2003).
79. Neri D, Bicknell R. Tumour vascular targeting. Nat. Rev. Cancer 5(6), 436-446 (2005). •• Discussion on the importance of the tumor endothelium and associated stroma for anticancer targeting strategies.
80. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat. Rev. Drug Discov. 5(2), 147-159 (2006).